Helena A. Yu

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Emmet Jordan, Hyunjae R. Kim, Maria E. Arcila et al. · Cancer Discovery · 2017 · 662 citations

Medicine, Molecular Genetics, Oncology +17

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping

Paul K. Paik, Alexander Drilon, Pang‐Dian Fan et al. · Cancer Discovery · 2015 · 571 citations · Full text

Medicine, Oncology, Pharmacology +15

<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane et al. · Journal of Clinical Oncology · 2018 · 471 citations

Medicine, Oncology, Pathology +17

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Emmett Jordan, Hyunjae R. Kim et al. · Clinical Cancer Research · 2017 · 460 citations

Medicine, Genetics, Oncology +16